HUE063811T2 - HIV-vírus-fertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek - Google Patents

HIV-vírus-fertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek

Info

Publication number
HUE063811T2
HUE063811T2 HUE19178148A HUE19178148A HUE063811T2 HU E063811 T2 HUE063811 T2 HU E063811T2 HU E19178148 A HUE19178148 A HU E19178148A HU E19178148 A HUE19178148 A HU E19178148A HU E063811 T2 HUE063811 T2 HU E063811T2
Authority
HU
Hungary
Prior art keywords
therapeutic
prophylactic
virus infection
compounds useful
hiv virus
Prior art date
Application number
HUE19178148A
Other languages
English (en)
Inventor
Michael Graupe
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59714166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE063811(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HUE063811T2 publication Critical patent/HUE063811T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/02Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/08Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE19178148A 2016-08-19 2017-08-17 HIV-vírus-fertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek HUE063811T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662377312P 2016-08-19 2016-08-19
US201762457555P 2017-02-10 2017-02-10

Publications (1)

Publication Number Publication Date
HUE063811T2 true HUE063811T2 (hu) 2024-02-28

Family

ID=59714166

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE17758388A HUE045137T2 (hu) 2016-08-19 2017-08-17 HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
HUE19178148A HUE063811T2 (hu) 2016-08-19 2017-08-17 HIV-vírus-fertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
HUS2200053C HUS2200053I1 (hu) 2016-08-19 2022-12-14 HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE17758388A HUE045137T2 (hu) 2016-08-19 2017-08-17 HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS2200053C HUS2200053I1 (hu) 2016-08-19 2022-12-14 HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek

Country Status (40)

Country Link
US (3) US10071985B2 (hu)
EP (3) EP3347352B1 (hu)
JP (4) JP6716785B2 (hu)
KR (4) KR102180740B1 (hu)
CN (2) CN109890808B (hu)
AU (4) AU2017312102B2 (hu)
BR (2) BR112018071678B1 (hu)
CA (1) CA3021227C (hu)
CL (1) CL2019000415A1 (hu)
CO (1) CO2019001379A2 (hu)
CR (1) CR20190084A (hu)
CY (1) CY1122296T1 (hu)
DK (2) DK3597646T3 (hu)
DO (1) DOP2019000033A (hu)
EC (1) ECSP19011209A (hu)
ES (2) ES2746374T3 (hu)
FI (1) FI3597646T3 (hu)
FR (1) FR22C1063I2 (hu)
HK (1) HK1256904B (hu)
HR (1) HRP20231018T1 (hu)
HU (3) HUE045137T2 (hu)
IL (1) IL264644B (hu)
JO (1) JOP20180123A1 (hu)
LT (3) LT3347352T (hu)
MA (2) MA42795B1 (hu)
MX (1) MX369307B (hu)
MY (1) MY191466A (hu)
NL (1) NL301212I2 (hu)
NZ (1) NZ750706A (hu)
PE (2) PE20211427A1 (hu)
PH (1) PH12019500335A1 (hu)
PL (2) PL3597646T3 (hu)
PT (2) PT3347352T (hu)
SA (1) SA519401123B1 (hu)
SG (2) SG11201808944QA (hu)
SI (2) SI3347352T1 (hu)
TW (4) TWI664966B (hu)
UY (1) UY37367A (hu)
WO (1) WO2018035359A1 (hu)
ZA (1) ZA201901430B (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
UY37367A (es) 2016-08-19 2018-03-23 Gilead Sciences Inc Nuevos compuestos para uso en el tratamiento de una infección viral y composiciones de los mismos
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) * 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
EP3752495B1 (en) * 2018-02-15 2023-07-19 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
AR114631A1 (es) 2018-02-16 2020-09-30 Gilead Sciences Inc Métodos e intermedios para preparar compuestos de piridina
WO2019246545A1 (en) * 2018-06-21 2019-12-26 Drexel University Small-molecule hiv-1 capsid protein inhibitors and methods using same
KR20210033492A (ko) * 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
WO2020031112A1 (en) * 2018-08-09 2020-02-13 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3849982A1 (en) 2018-09-14 2021-07-21 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3853228A1 (en) 2018-09-20 2021-07-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2020084491A1 (en) 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7398448B2 (ja) 2018-10-24 2023-12-14 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
US20210393633A1 (en) 2018-10-25 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
ES2969030T3 (es) 2018-10-29 2024-05-16 Viiv Healthcare Uk No 5 Ltd Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana
US20210379071A1 (en) 2018-11-05 2021-12-09 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3877387A1 (en) 2018-11-05 2021-09-15 ViiV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
EP3962603A1 (en) 2019-04-30 2022-03-09 ViiV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20210323967A1 (en) 2019-06-19 2021-10-21 Viiv Healthcare Uk (No. 5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
US20220389007A1 (en) 2019-10-01 2022-12-08 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
JP2022551256A (ja) 2019-10-01 2022-12-08 ビーブ、ヘルスケア、ユーケー、(ナンバー5)、リミテッド ヒト免疫不全ウイルスの複製阻害剤
TW202128648A (zh) 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
US20220370451A1 (en) 2019-10-08 2022-11-24 VIIV HEALTHCARE UK ( No. 5) LIMITED Inhibitors of human immunodeficiency virus replication
KR20220106165A (ko) 2019-11-26 2022-07-28 길리애드 사이언시즈, 인코포레이티드 Hiv의 예방을 위한 캡시드 억제제
WO2021107066A1 (ja) 2019-11-28 2021-06-03 塩野義製薬株式会社 インテグラーゼ阻害剤及び抗hiv薬を組み合わせることを特徴とするhiv感染症の予防及び治療用医薬
EP4067349A4 (en) * 2019-11-29 2022-12-21 Jiangsu Hengrui Pharmaceuticals Co., Ltd. FUSED PYRIDINE CYCLE DERIVATIVE, METHOD FOR PREPARATION AND PHARMACEUTICAL USE
CN116098917A (zh) * 2020-02-27 2023-05-12 河南真实生物科技有限公司 核苷类化合物在治疗冠状病毒感染性疾病中的用途
CN115551858A (zh) 2020-03-06 2022-12-30 Viiv保健英国第五有限公司 人类免疫缺陷病毒复制的抑制剂
JP2023517312A (ja) 2020-03-06 2023-04-25 ビーブ、ヘルスケア、ユーケー、(ナンバー5)、リミテッド ヒト免疫不全ウイルスの複製阻害剤
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ, インコーポレイテッド 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
BR112022020933A2 (pt) 2020-04-15 2022-12-06 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
EP4153181A1 (en) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
JP2023533915A (ja) * 2020-06-25 2023-08-07 ギリアード サイエンシーズ, インコーポレイテッド Hivの治療のためのカプシド阻害剤
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN116437958A (zh) 2020-11-11 2023-07-14 吉利德科学公司 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
CA3204255A1 (en) 2021-01-25 2022-07-28 Lianhong Xu Combination therapy for hiv with adenosine derivative and capsid inhibitors
TW202313584A (zh) * 2021-05-28 2023-04-01 大陸商江蘇恒瑞醫藥股份有限公司 稠合吡啶環衍生物的可藥用鹽、晶型及其製備方法
KR20230019059A (ko) 2021-07-30 2023-02-07 (주) 에빅스젠 연전초 추출물을 유효성분으로 포함하는, 바이러스성 질환 완화 및 개선용 조성물
KR20230018690A (ko) 2021-07-30 2023-02-07 (주) 에빅스젠 둥근이질풀 추출물을 유효성분으로 포함하는, 바이러스성 질환 치료 및 개선용 조성물
CA3235937A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
US20230203071A1 (en) * 2021-12-03 2023-06-29 Zhimin Du Therapeutic compounds for hiv virus infection
TW202342447A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於hiv病毒感染之治療性化合物
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
KR20240061218A (ko) 2022-10-31 2024-05-08 주식회사 이보드 복합 단열재 및 제조방법

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DK0533833T3 (da) 1990-06-13 1996-04-22 Arnold Glazier Phosphorprolægemidler
ES2118069T3 (es) 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
NZ535408A (en) 2000-07-21 2006-09-29 Gilead Sciences Inc Method for selecting prodrugs of phosphonate nucleotide analogues
EP1399433B1 (en) 2001-06-27 2007-08-22 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
JP4300108B2 (ja) 2001-06-27 2009-07-22 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのピロリジン類
PT1441734E (pt) 2001-10-26 2007-05-31 Isti Di Ric Di Bio Moleco P An Di-hidroxipirimidinocarboxamidas inibidoras da integrase do vih
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
ES2327544T3 (es) 2004-02-27 2009-10-30 Schering Corporation Compuestos novedosos como inhibidores de serina proteasa ns3 de virus de hepetitis c.
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
US8067587B2 (en) 2005-07-28 2011-11-29 Lenroc Company Process for the production of monoalkali metal cyanurates
RU2008101923A (ru) 2005-08-05 2009-09-10 Астразенека Аб (Se) Трициклические бензимидазолы и их применение в качестве модуляторов метаботропного глутаматного рецептора
NZ568595A (en) 2005-12-14 2010-04-30 Bristol Myers Squibb Co Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
EP2010493B1 (en) 2006-04-12 2016-01-27 Merck Sharp & Dohme Corp. Pyridyl amide t-type calcium channel antagonists
US7647464B2 (en) 2006-04-28 2010-01-12 At&T Intellectual Property, I,L.P. Methods, systems, and products for recording media to a restoration server
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US8124811B2 (en) 2007-03-20 2012-02-28 Allylix, Inc. Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
CA2681718A1 (en) 2007-03-23 2008-10-02 University Of Massachusetts Hiv-1 protease inhibitors
AR068794A1 (es) 2007-06-29 2009-12-09 Gilead Sciences Inc Compuestos antivirales
JP5701057B2 (ja) 2007-07-12 2015-04-15 ヤンセン サイエンシズ アイルランド ユーシー (e)4−[[4−[[4−(2−シアノエテニル)−2,6−ジメチルフェニル]アミノ]−2−ピリミジニル]アミノ]ベンゾニトリルの結晶形
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
AU2008317353B2 (en) 2007-10-24 2014-08-07 Merck Sharp & Dohme Llc Heterocycle phenyl amide T-type calcium channel antagonists
JP2011500808A (ja) 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドt型カルシウムチャネルアンタゴニスト
EA019259B1 (ru) 2007-11-16 2014-02-28 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
JP5537442B2 (ja) 2008-03-13 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー 第xia因子阻害剤としてのピリダジン誘導体
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
EA201171046A1 (ru) 2009-02-25 2012-04-30 Бигтек Прайвит Лимитед Зонды и праймеры для детектирования вируса чикунгуньи
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
WO2011143772A1 (en) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibitors of hiv replication
PE20130525A1 (es) 2010-07-02 2013-05-05 Gilead Sciences Inc Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih
ES2634490T3 (es) 2010-07-02 2017-09-28 Gilead Sciences, Inc. Derivados de ácido napht-2-ylacetico para tratar el sida
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
KR102129247B1 (ko) 2011-03-23 2020-07-06 트레베나, 인코포레이티드. 오피오이드 수용체 리간드와 그 용도 및 제조방법
AU2012245187B2 (en) 2011-04-21 2016-06-30 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
IN2014DN01012A (hu) 2011-08-16 2015-05-15 Gilead Sciences Inc
WO2013091096A1 (en) 2011-12-20 2013-06-27 Boehringer Ingelheim International Gmbh Condensed triclyclic compounds as inhibitors of hiv replication
CA2850881C (en) 2012-04-20 2021-02-16 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
US9447134B2 (en) 2012-08-17 2016-09-20 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
SG11201504857SA (en) 2012-12-21 2015-07-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US20140221380A1 (en) 2012-12-27 2014-08-07 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
ES2614053T3 (es) 2013-01-09 2017-05-29 Gilead Sciences, Inc. Heteroarilos de 5 miembros y su uso como antivirales
NZ727792A (en) 2013-01-09 2018-04-27 Gilead Sciences Inc Therapeutic compounds
EP2769722A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
TWI694071B (zh) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
CN106458940A (zh) 2013-10-24 2017-02-22 百时美施贵宝公司 人类免疫缺陷病毒复制的抑制剂
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
AU2015308907B2 (en) 2014-08-29 2018-10-18 Gilead Sciences, Inc. Antiretroviral agents
WO2016040084A1 (en) 2014-09-09 2016-03-17 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
BR112017022544A2 (pt) 2015-04-23 2018-07-10 Viiv Healthcare Uk No 5 Ltd ?composto, composição, e, método para tratamento de infecção por hiv?.
AR104389A1 (es) 2015-04-23 2017-07-19 Bristol Myers Squibb Co Inhibidores de la replicación del virus de inmunodeficiencia humana
KR102443575B1 (ko) * 2015-07-06 2022-09-16 길리애드 사이언시즈, 인코포레이티드 Cot 조정제 및 그의 사용 방법
US10171985B1 (en) 2015-07-22 2019-01-01 Ginko LLC Method and apparatus for data sharing
UY37367A (es) 2016-08-19 2018-03-23 Gilead Sciences Inc Nuevos compuestos para uso en el tratamiento de una infección viral y composiciones de los mismos
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
UY37710A (es) 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
TW202024061A (zh) * 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
EP3752495B1 (en) 2018-02-15 2023-07-19 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
AR114631A1 (es) 2018-02-16 2020-09-30 Gilead Sciences Inc Métodos e intermedios para preparar compuestos de piridina
US10911396B2 (en) 2018-06-28 2021-02-02 Paypal, Inc. Mid-tier messaging system
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
KR20220106165A (ko) 2019-11-26 2022-07-28 길리애드 사이언시즈, 인코포레이티드 Hiv의 예방을 위한 캡시드 억제제
JP2023533915A (ja) 2020-06-25 2023-08-07 ギリアード サイエンシーズ, インコーポレイテッド Hivの治療のためのカプシド阻害剤

Also Published As

Publication number Publication date
WO2018035359A1 (en) 2018-02-22
CL2019000415A1 (es) 2019-06-21
ES2954514T3 (es) 2023-11-22
AU2017312102B2 (en) 2020-03-05
JOP20180123A1 (ar) 2019-01-30
TW201811327A (zh) 2018-04-01
AU2021221855B2 (en) 2023-08-31
SG10201912535VA (en) 2020-02-27
SI3597646T1 (sl) 2023-10-30
MY191466A (en) 2022-06-28
TWI715944B (zh) 2021-01-11
MA50673A (fr) 2020-08-05
ES2746374T3 (es) 2020-03-05
PT3347352T (pt) 2019-09-24
TW202342449A (zh) 2023-11-01
CA3021227C (en) 2020-11-03
AU2020202331C1 (en) 2021-08-26
UY37367A (es) 2018-03-23
US20180370950A1 (en) 2018-12-27
PL3347352T3 (pl) 2019-12-31
MX369307B (es) 2019-11-05
CN111793061A (zh) 2020-10-20
MA42795B1 (fr) 2019-08-30
AU2017312102A1 (en) 2019-03-07
NL301212I2 (nl) 2023-04-06
AU2021221855A1 (en) 2021-09-23
KR20200131351A (ko) 2020-11-23
US11993583B2 (en) 2024-05-28
NL301212I1 (hu) 2023-01-12
EP3347352B1 (en) 2019-07-03
EP3597646A1 (en) 2020-01-22
JP6716785B2 (ja) 2020-07-01
US20180051005A1 (en) 2018-02-22
PH12019500335A1 (en) 2019-11-11
PT3597646T (pt) 2023-09-11
EP3597646B1 (en) 2023-06-21
KR20240070646A (ko) 2024-05-21
AU2020202331B2 (en) 2021-05-27
IL264644B (en) 2019-09-26
CN109890808A (zh) 2019-06-14
JP2019528280A (ja) 2019-10-10
AU2020202331A1 (en) 2020-04-23
LTPA2023501I1 (hu) 2023-02-10
EP4265299A2 (en) 2023-10-25
TWI664966B (zh) 2019-07-11
BR112018071678B1 (pt) 2021-01-26
CR20190084A (es) 2019-05-02
AU2023271739A1 (en) 2023-12-14
JP2023011754A (ja) 2023-01-24
CY1122296T1 (el) 2021-01-27
LT3597646T (lt) 2023-09-25
NZ750706A (en) 2020-07-31
SI3347352T1 (sl) 2019-08-30
DK3597646T3 (da) 2023-09-04
CA3021227A1 (en) 2018-02-22
KR20190039431A (ko) 2019-04-11
EP3347352A1 (en) 2018-07-18
HUE045137T2 (hu) 2019-12-30
PE20190910A1 (es) 2019-06-26
SG11201808944QA (en) 2018-11-29
KR20230011471A (ko) 2023-01-20
DOP2019000033A (es) 2019-03-15
BR112018071678A2 (pt) 2019-02-19
DK3347352T3 (da) 2019-08-26
SA519401123B1 (ar) 2022-11-09
HK1256904B (zh) 2020-07-17
EP4265299A3 (en) 2024-01-17
TW201922711A (zh) 2019-06-16
HRP20231018T1 (hr) 2023-12-08
CN109890808B (zh) 2020-08-07
KR102180740B1 (ko) 2020-11-20
PL3597646T3 (pl) 2023-12-11
US20200262815A1 (en) 2020-08-20
ECSP19011209A (es) 2019-02-28
FR22C1063I2 (fr) 2023-12-15
MA42795A (fr) 2019-07-03
PE20211427A1 (es) 2021-08-03
MX2018012905A (es) 2019-01-30
US10071985B2 (en) 2018-09-11
CO2019001379A2 (es) 2019-02-19
FI3597646T3 (fi) 2023-09-07
JP2021008516A (ja) 2021-01-28
TW202138365A (zh) 2021-10-16
US10654827B2 (en) 2020-05-19
ZA201901430B (en) 2021-09-29
FR22C1063I1 (fr) 2023-02-03
HUS2200053I1 (hu) 2023-01-28
JP2020111592A (ja) 2020-07-27
LT3347352T (lt) 2019-08-12
BR122020001791B1 (pt) 2022-01-25

Similar Documents

Publication Publication Date Title
HUS2200053I1 (hu) HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
HK1251554A1 (zh) 用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
HK1248711A1 (zh) 用於治療和預防病毒感染的新的取代的氨基噻唑並嘧啶二酮
EP3490987A4 (en) NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF HBV INFECTION.
HK1245784A1 (zh) 用於治療和預防乙型肝炎病毒感染的新的6-稠合的雜芳基二氫嘧啶
IL284255A (en) 7-substituted sulfonimidylpurinone compounds for the treatment and prevention of viral infection
EP3474863A4 (en) PHOSPHORAMIDATE FOR TREATING THE HEPATITIS C VIRUS
IL280769A (en) New sulfonimidylpurinone compounds and their history for the treatment and prevention of virus infection
PT3519569T (pt) Vetores de vírus adenoassociados para o tratamento de mucopolissacaridoses
EP3137078A4 (en) Treatment of hepatitis delta virus infection
EP3370723A4 (en) TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
EP3226973A4 (en) Treatment of hepatitis delta virus infection
EP3448377A4 (en) METHODS FOR THE TREATMENT OF AN INFECTION
ZA201900770B (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
LT3504210T (lt) Nauji 7 padėtyje pakeisti sulfonimidoilpurinono junginiai, skirti viruso sukeliamos infekcijos gydymui ir profilaktikai